In vivotests - Brightening effect
20 healthy female volunteers aged 18 to 46, with a range of skin types were selected for this study. The volunteers applied a cream containing 0.1% Skinbright Active on one side of the face, twice daily, for 2 months, and a placebo cream on the other side.
The brightening effect was instrumentally evaluated by means of a Chromameter CR-300. Mean values from 5 successive measurements were calculated. These 6 measurements were rigorously made at the same location at each time.
Measurements were taken before application, after 30 days and after 60 days of treatment.
After 30 days of treatment, there was significant increase in skin luminance for the skin that was treated with Skinbright Active Cream. The placebo cream presented no significant effects.
After 60 days of treatment, the brightening effect induced by the cream containing Skinbright Active increased in respect to the results at 30 days and it was significantly superior to the effect observed for the placebo cream. In short, the results of the in vivo test prove that Skinbright Active is able to induce a skin brightening effect after 30 and 60 days of treatment.
At the end of the study, no adverse effects were reported by the volunteers.
Skinbright Active showed no cytotoxic effects on melanocytes, keratinocytes or fibroblasts, neither mutagenicity nor any irritation or sensitisation reaction. Its efficacy was tested in cell-free enzymatic assays as well as in cell-based assays. It proved to inhibit both mushroom and endogenous human tyrosinase in vitro, and exhibited a significant depigmenting effect on human melanocytes. The product also proved to have a significant photo-protective effect on human epidermal keratinocyte cell cultures, and can therefore prevent the skin-damaging effects of ultraviolet radiation.
In conclusion, Skinbright Active can be classified as a safe skin brightening agent due to its impeccable safety profile and contrasted in vitro and in vivo efficacy.
I really love it and work perfectly